Comments
Loading...

NYLI Candriam U.S. Mid Cap Equity ETF

IQSMARCA
Logo brought to you by Benzinga Data
$33.79
-0.29-0.85%
At close: -
Sector
Consumer Cyclical
Region
US
AUM
222.90M
Fund Score

NYLI Candriam U.S. Mid Cap Equity ETF (ARCA:IQSM) Quotes, Forecast and News Summary

NYLI Candriam U.S. Mid Cap Equity ETF (ARCA: IQSM) stock price, news, charts, stock research, profile.

Open$34.21
High$34.21
52 Wk High$35.34
AUM222.90M
Dividend$0.35
Ex-Div DateJun 21, 2024
Volume577
Market Cap$9.88B
Mgmt Fee0.15%
P/E Ratio18.44
Prev. Close$34.08
Low$33.79
52 Wk Low$29.66
Shares Out6.70M
Yield1.13%
Div. FreqQuarterly
Avg. Volume Daily4.18K
Beta1.25
Avg. Expense Ratio0.15%
P/B Ratio2.66

FAQ

Q

How do I buy NYLI Candriam U.S. Mid Cap Equity ETF (IQSM) stock?

A

You can purchase shares of NYLI Candriam U.S. Mid Cap Equity ETF (ARCA:IQSM) through any online brokerage.

View our list of the best stock brokerages

Q

Who are NYLI Candriam U.S. Mid Cap Equity ETF (IQSM) competitors?

A

There are no as such competitors for NYLI Candriam U.S. Mid Cap Equity ETF.

Q

What is the forecast, or price target, for NYLI Candriam U.S. Mid Cap Equity ETF (IQSM) stock?

A

There is no analysis for NYLI Candriam U.S. Mid Cap Equity ETF to provide a consensus price target.

Q

What is the current price for NYLI Candriam U.S. Mid Cap Equity ETF (IQSM)?

A

The stock price for NYLI Candriam U.S. Mid Cap Equity ETF (ARCA: IQSM) is $26.84 last updated September 25, 2023 at 4:02 PM EDT.

Q

Does NYLI Candriam U.S. Mid Cap Equity ETF (IQSM) pay a dividend?

A

There are no upcoming dividends for NYLI Candriam U.S. Mid Cap Equity ETF.

Q

When is NYLI Candriam U.S. Mid Cap Equity ETF (ARCA:IQSM) reporting earnings?

A

NYLI Candriam U.S. Mid Cap Equity ETF does not have any upcoming earnings scheduled.

Q

Is NYLI Candriam U.S. Mid Cap Equity ETF (IQSM) going to split?

A

There is no upcoming split for NYLI Candriam U.S. Mid Cap Equity ETF.

Open$34.21
High$34.21
52 Wk High$35.34
AUM222.90M
Dividend$0.35
Ex-Div DateJun 21, 2024
Volume577
Market Cap$9.88B
Mgmt Fee0.15%
P/E Ratio18.44
Prev. Close$34.08
Low$33.79
52 Wk Low$29.66
Shares Out6.70M
Yield1.13%
Div. FreqQuarterly
Avg. Volume Daily4.18K
Beta1.25
Avg. Expense Ratio0.15%
P/B Ratio2.66
ETF Details
SectorConsumer Cyclical
CategoryMid Performer-High Growth
Investment StyleMid Cap Blend
Fund InceptionOct 25, 2022
Managers
James Harrison
Greg Barrato
DefinitionStocks with average financial performance and superior growth potential lead this Equity Fund portfolio
Investment Policy
The Fund generally will invest in all of the securities that comprise its Underlying Index in proportion to their weightings in the Underlying Index. Under normal circumstances, the Fund will invest at least 80% of its assets in instruments that meet the Underlying Indexs environmental, social, and corporate governance (ESG) criteria. The Fund has adopted a policy to invest, under normal circumstances, at least 80% of the value of its assets (net assets plus the amount of any borrowings for investment purposes) in U.S. equity securities of mid-capitalization companies. The Fund employs a 'passive management' - or indexing - investment approach designed to track the performance of the Underlying Index, which was developed by IndexIQ LLC (IndexIQ) with Candriam (Candriam) acting as index consultant to IndexIQ. In its role as index consultant, Candriam assists IndexIQ with the development, calculation and maintenance of the Underlying Index, including the ESG security selection process for the Underlying Index. The Underlying Index is designed to deliver exposure to equity securities of companies meeting environmental, social and corporate governance (ESG) criteria developed by Candriam and weighted using a market-capitalization weighting methodology.
Top ETF Holdings
SymbolNameShare %
GDDYGodaddy Inc. Class A1.03%
EMEE M C O R Group Inc.0.96%
PKGPackaging Corp. Of Ame...0.90%
BURLBurlington Stores Usd0...0.87%
GENGen Digital Inc0.86%
MANHManhattan Associates I...0.84%
OCOwens Corning0.84%
UTHRUtd Therapeutic Com Us...0.82%
MASMasco Corp.0.81%
SRPTSarepta Therapeutics I...0.77%